EDTA Chelation Therapy Failed to Reduce Heart Risks
A study of adults with diabetes and past heart attacks found no cardiovascular benefit from the chelation treatment.
Updated on Oct. 6, 2026 in Heart Disease
Live Poll
Does evidence that a medical treatment is ineffective make you less trusting of similar clinical trials?
The TACT2 clinical trial involving 1,000 participants found that edetate disodium-based chelation therapy did not reduce cardiovascular events in people with diabetes and a history of myocardial infarction. The treatment failed to provide a heart-health advantage despite its ability to lower blood lead levels.
Why it matters
This study clarifies the role of chelation therapy in managing secondary heart disease risks for patients with diabetes. It marks a significant result for those considering heavy metal removal as a strategy to prevent repeat cardiac events.
In a randomized trial of 1,000 participants, researchers compared 40 weekly EDTA infusions against a placebo solution. The study concluded that despite effectively reducing blood lead levels, the therapy did not decrease the rate of cardiovascular events over a 60-month follow-up period.
The players
TACT2
A clinical trial specifically designed to evaluate the cardiovascular outcomes of chelation therapy in patients with diabetes.
The details
The trial tested whether removing accumulated heavy metals from the body could improve cardiovascular health through a process known as chelation. Participants received up to 3 grams of disodium EDTA per infusion, which works by binding to metals in the bloodstream to facilitate their excretion. However, the study findings indicate that this process does not translate into improved outcomes for the heart in patients with pre-existing diabetes and a prior heart attack.
Timeline
The original TACT study reported an 18% reduction in cardiovascular events in 2013.
The TACT2 study tracked participants for a total duration of 60 months.
Health Landscape
The TACT2 results stand in contrast to findings from the 2013 TACT trial, which suggested potential benefits in cardiovascular risk reduction. This study effectively clarifies the limitations of chelation therapy for patients managing heart disease complications alongside diabetes.
If you are managing diabetes and heart disease, discuss the most evidence-backed prevention strategies with your cardiologist or primary care doctor. Relying on chelation as a heart-protective treatment is not supported by this latest trial data.
The takeaway
This study demonstrates that chelation therapy is not an effective way to reduce heart event risks in patients with diabetes. Patients should focus on evidence-based management strategies like blood sugar control and blood pressure monitoring in consultation with their medical team.
Further reading
For more information on managing chronic conditions, explore our Heart Disease section.
More information
Review the full details of the research via the study data access portal.
Source note: This article includes information reported by The National Center for Biotechnology Information.
Live Poll
Does evidence that a medical treatment is ineffective make you less trusting of similar clinical trials?
